ENTRY       D11916                      Drug
NAME        Vutrisiran sodium (JAN);
            Amvuttra (TN)
PRODUCT     AMVUTTRA (Alnylam Pharmaceuticals)
FORMULA     C530H672F9N171O323P43S6.43Na
EXACT_MASS  17281.3914
MOL_WEIGHT  17289.7661
REMARK      Therapeutic category: 1290
            ATC code: N07XX18
            Chemical structure group: DG03127
            Product (DG03127): D11916<JP/US>
EFFICACY    Gene expression regulator
  DISEASE   Polyneuropathy of hereditary transthyretin-mediated amyloidosis [DS:H00845]
  TYPE      RNA interference (RNAi) drug
COMMENT     Treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis)
TARGET      TTR [HSA:7276] [KO:K20731] (mRNA)
  PATHWAY   hsa04918(7276)  Thyroid hormone synthesis
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             N NERVOUS SYSTEM
              N07 OTHER NERVOUS SYSTEM DRUGS
               N07X OTHER NERVOUS SYSTEM DRUGS
                N07XX Other nervous system drugs
                 N07XX18 Vutrisiran
                  D11916  Vutrisiran sodium (JAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
              Vutrisiran
               D11916  Vutrisiran sodium (JAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             1  Agents affecting nervous system and sensory organs
              12  Agents affecting peripheral nervous system
               129  Miscellaneous
                1290  Miscellaneous
                 D11916  Vutrisiran sodium (JAN)
            Target-based classification of drugs [BR:br08310]
             Transporters
              Other transporters
               Others
                TTR
                 D11916  Vutrisiran sodium (JAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11916
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11916
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11916
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11916
///
